

# Rapid antiretroviral therapy start and restart for justice-involved people living with HIV in the Illinois Department of Corrections

The Department of Pharmacy Practice

Fola Arowora<sup>1</sup> PharmD Candidate 2026, MPH, MPP, MHS, Emily Drwiega<sup>1</sup>, PharmD, Mahesh Patel<sup>2</sup>, MD, Melissa E. Badowski<sup>1</sup>, PharmD, MPH <sup>1</sup>University of Illinois Chicago, Retzky College of Pharmacy, Chicago, IL, USA <sup>2</sup>University of Illinois Chicago, College of Medicine, Chicago, IL, USA

# Background

- Rapid ART initiation improves outcomes: Early antiretroviral therapy (ART) is clinically proven to reduce HIV-related morbidity, mortality, and transmission, particularly when started immediately after diagnosis.<sup>1</sup>
- Limited evidence in corrections: While rapid ART has shown success in outpatient settings, data on its implementation and outcomes in populations in-custody, especially for those restarting therapy, remains limited.<sup>2</sup>
- Gaps in carceral HIV care: Justice-involved individuals face systemic delays in diagnosis and ART access, leading to poor linkage to care, higher rates of viral rebound, and community transmission.<sup>3</sup>
- Patients who are treatment-experienced are underrepresented: Rapid ART studies exclude individuals with prior ART exposure, leaving uncertainty about safety and efficacy in those reinitiating therapy after lapses.
- Study aims: This study evaluates rapid ART initiation and re-initiation among adults incustody with new or prior HIV diagnoses, using a structured telemedicine model within the Illinois Department of Corrections (IDOC).

# **Methods**

### Study Design & Population

Retrospective cohort analysis of adults diagnosed with HIV (ART-naïve or treatmentexperienced) and in-custody in the IDOC between January 1, 2021, and June 30, 2024.

### **Telemedicine-Based Rapid ART Model**

All individuals received rapid ART initiation or restart at their first post-intake visit with a multidisciplinary HIV care team via telemedicine at UI Health.

### **ART Selection & Resistance Evaluation**

- Individuals who were ART-naïve underwent baseline resistance testing when feasible.
- Treatment-experienced individuals were restarted on ART based on guideline-based therapy, clinical history, and genotypic data, if available.

### Statistical Analysis

Descriptive statistics summarized demographic data and clinical outcomes. Paired t-tests and Chi-square tests assessed differences in CD4 count and virologic suppression, respectively. Significance was defined as p < 0.05.

### Inclusion Criteria

- Adults with HIV while in IDOC custody
- ART-naïve or treatment-experienced individuals eligible for rapid ART
- Followed by UI Health's multidisciplinary HIV care team via telemedicine

### Exclusion Criteria

- No confirmed HIV diagnosis during time in IDOC custody
- Did not initiate or restart ART at the first post-intake appointment


### **Primary Endpoint:**

- Proportion of justice-involved individuals with new or prior HIV diagnoses who achieved viral suppression at first follow-up (HIV RNA <200 copies/mL) following rapid ART initiation or re-initiation while in-custody

#### Secondary Endpoint:


Change in CD4 cell count from baseline to first follow-up among individuals starting or restarting rapid ART


ole 1. Baseline C	haracteristics and Outcomes of F	Patients wh	o were T
	Baseline		Foll
Age, n (%)	20 – 30 years	5 (23)	
	31 – 40 years	11 (50)	
	41 – 50 years	5 (23)	
	>51 years	1 (5)	
Gender, n (%)	Male	21 (95)	
	Female	0 (0)	
	Transgender Female	1 (5)	
Ethnicity	Black	16 (73)	
	White	5 (23)	
	Latino	1 (5)	
CD4 count,	444 (range: 113 – 1127 cells/mm³)		553 (rai
average (range)			905 ce
VL, n(%)	<200 copies/mL	0 (0)	21
	≥200 copies/mL	22 (100)	1
Genotype	Yes	17 (77)	
obtained	No	4 (18)	
	Obtained, unable to sequence	1 (5)	
Rapid Start	Bictegravir/emtricitabine/tenofovir	15 (68)	15
Agent	alafenamide		
	Dolutegravir/lamivudine	7 (32)	7



	Baseline		Follow-up
Age, n (%)	20 – 30 years	3 (20)	
	31 – 40 years	7 (47)	
	41 – 50 years	4 (26)	]
	>51 years	1 (7)	1
Gender, n (%)	Male	12 (80)	]
	Female	2 (13)	
	Transgender Female	1 (7)	
CD4 count,	562 (range: 95 – 760 cells/mm <sup>3</sup> )		633 (range
average (range)			1073 cells/
VL, n(%)	<200 copies/mL	3 (20)	15 (100%)
	≥200 copies/mL	12 (80)	0 (0%)
Genotype	Yes	1 (7)	
obtained	No	14 (93)	
Rapid Re-Start	Bictegravir/emtricitabine/tenofovir	12 (80)	12 (80)
Agent	alafenamide		
	Dolutegravir/lamivudine	1 (7)	1 (7)
	Dolutegravir/lamivudine/abacavir	1 (7)	1 (7)
	Rilpivirine/ emtricitabine/tenofovir	1 (7)	(7)
	alafenamide		

Fig.B: Viral Suppression in Patients who are Treatment-Experienced





📲 UI Health | 🚥